Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
ONCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.33 - $1.53
Previous CloseN/A
Volume216.96K
Average Volume (3M)1.31M
Market Cap
$92.81M
Enterprise Value$52.56M
Total Cash (Recent Filing)$15.30M
Total Debt (Recent Filing)$1.00M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 12, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding96,602,020
10 Day Avg. Volume1,026,711
30 Day Avg. Volume1,312,383
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-536.28
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$3.88Price Target Upside321.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical DataExperts from top global institutions find the existing data for pelareorep in metastatic pancreatic ductal adenocarcinoma both biologically and clinically compelling.
Intellectual PropertyThe company expects to extend intellectual property protection for pelareorep by up to 20 years, which would strengthen its position in the market.
Regulatory ProgressOncolytics Biotech is leveraging its Fast Track and Orphan Drug designations to accelerate consultation with the FDA and EMA regulators, aiming for an efficient regulatory path forward for its lead program.
Bears Say
Financial NeedsThere is an immediate need for capital.
Management And StrategyOncolytics is continuing to actively search for a Chief Executive Officer, as well as exploring potential BD opportunities.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.33 and its highest was $1.53 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $92.81M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 08, 2025. The company reported -$0.051 earnings per share for the quarter, beating the consensus estimate of -$0.073 by $0.023.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.08.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 96,602,020 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.051 in its last earnings report, beating expectations of -$0.073. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
Oncolytics Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.88 (321.74% Upside)
$3.88 (321.74% Upside)
Insider Transactions
Bought Shares
Worth $130.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 17.0%
Last 30 Days ▲ 17.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.92%
12-Months-Change
Fundamentals
Return on Equity
-211.24%
Trailing 12-Months
Asset Growth
-46.69%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, especially in breast and pancreatic cancers, and a solid financial position with new capital access. However, the ongoing search for a new CEO and a decrease in R&D spending present challenges. The overall sentiment is cautiously optimistic with key strategic advancements underway.View all ONCY earnings summariesONCY Stock 12 Month Forecast
Average Price Target
$3.88
▲(321.74% Upside)
Technical Analysis
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
Covalon Technologies
―
Helix BioPharma
―
Sernova
―
Ownership Overview
1.44% Insiders
0.07% Mutual Funds
0.05% Other Institutional Investors
98.44% Public Companies and Individual Investors
Options Prices
Currently, No data available
---